Style | Citing Format |
---|---|
MLA | Zeraati MR, et al.. "Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization." Journal of Obstetrics# Gynecology and Cancer Research, vol. 8, no. 1, 2023, pp. 86-94. |
APA | Zeraati MR, Torkmandi H, Abdi M, Jamshidi MR, Safaie A (2023). Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization. Journal of Obstetrics# Gynecology and Cancer Research, 8(1), 86-94. |
Chicago | Zeraati MR, Torkmandi H, Abdi M, Jamshidi MR, Safaie A. "Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization." Journal of Obstetrics# Gynecology and Cancer Research 8, no. 1 (2023): 86-94. |
Harvard | Zeraati MR et al. (2023) 'Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization', Journal of Obstetrics# Gynecology and Cancer Research, 8(1), pp. 86-94. |
Vancouver | Zeraati MR, Torkmandi H, Abdi M, Jamshidi MR, Safaie A. Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization. Journal of Obstetrics# Gynecology and Cancer Research. 2023;8(1):86-94. |
BibTex | @article{ author = {Zeraati MR and Torkmandi H and Abdi M and Jamshidi MR and Safaie A}, title = {Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization}, journal = {Journal of Obstetrics# Gynecology and Cancer Research}, volume = {8}, number = {1}, pages = {86-94}, year = {2023} } |
RIS | TY - JOUR AU - Zeraati MR AU - Torkmandi H AU - Abdi M AU - Jamshidi MR AU - Safaie A TI - Malignant Hyperthermia, Cardiac Dysrhythmia and Hypertension Crisis in Sublingual Misoprostol: Educational Policy for Adverse Drug Reaction Organization JO - Journal of Obstetrics# Gynecology and Cancer Research VL - 8 IS - 1 SP - 86 EP - 94 PY - 2023 ER - |